Seven Eight Capital’s Puma Biotechnology PBYI Stock Holding History

Seven Eight Capital’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-35,132	Closed	-$1.36M	–	698
2019 Q1	$1.36M	Sell	35,132 -27,800	-44%	-$849K	0.07%	312
2018 Q4	$1.28M	Buy	62,932 +1,296	+2%	+$38.9K	0.07%	318
2018 Q3	$2.83M	Buy	+61,636	New	+$2.97M	0.17%	181
2017 Q3	–	Sell	-13,809	Closed	-$1.21M	–	565
2017 Q2	$1.21M	Buy	+13,809	New	+$772K	0.17%	183
2016 Q4	–	Sell	-33,400	Closed	-$2.24M	–	631
2016 Q3	$2.24M	Buy	+33,400	New	+$1.69M	0.65%	43
2015 Q3	–	Sell	-1,000	Closed	-$117K	–	645
2015 Q2	$117K	Buy	+1,000	New	+$181K	0.14%	243

Other funds holding PBYI

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Seven Eight Capital's PBYI Position: Q2 2019 in Review

Seven Eight Capital sold out of Puma Biotechnology (PBYI) in Q2 2019, closing a stake of 35,132 shares — an estimated $1.36M sold.

Seven Eight Capital first reported a position in PBYI in Q2 2015 and held it in 6 quarters. The position peaked at $2.83M in Q3 2018. 139 funds tracked by Wall St. Rank hold PBYI as of Q2 2019.

Seven Eight Capital reported no remaining Puma Biotechnology position as of Q2 2019 after selling out during the quarter.
Seven Eight Capital sold 35,132 Puma Biotechnology shares in Q2 2019, an estimated $1.36M.
Seven Eight Capital first reported a position in Puma Biotechnology in Q2 2015 and held it in 6 quarters.
Seven Eight Capital's Puma Biotechnology position peaked at $2.83M in Q3 2018.
139 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2019.

Based on Seven Eight Capital's 13F filing for Q2 2019, filed 12 Aug 2019.